XENE vs. IDYA, JANX, HCM, ARWR, FOLD, PBH, RARE, AXSM, BHVN, and MRUS
Should you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Axsome Therapeutics (AXSM), Biohaven (BHVN), and Merus (MRUS). These companies are all part of the "pharmaceutical preparations" industry.
Xenon Pharmaceuticals (NASDAQ:XENE) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
IDEAYA Biosciences has higher revenue and earnings than Xenon Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 5.4% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Xenon Pharmaceuticals presently has a consensus price target of $59.11, indicating a potential upside of 46.03%. IDEAYA Biosciences has a consensus price target of $46.80, indicating a potential upside of 13.95%. Given Xenon Pharmaceuticals' higher probable upside, research analysts clearly believe Xenon Pharmaceuticals is more favorable than IDEAYA Biosciences.
In the previous week, IDEAYA Biosciences had 5 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 31 mentions for IDEAYA Biosciences and 26 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.44 beat IDEAYA Biosciences' score of 0.34 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.
Xenon Pharmaceuticals has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -483.05%. IDEAYA Biosciences' return on equity of -20.09% beat Xenon Pharmaceuticals' return on equity.
Xenon Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Xenon Pharmaceuticals received 294 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 69.39% of users gave Xenon Pharmaceuticals an outperform vote while only 67.86% of users gave IDEAYA Biosciences an outperform vote.
Summary
Xenon Pharmaceuticals beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.
Get Xenon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenon Pharmaceuticals Competitors List
Related Companies and Tools
